Примери за използване на Discontinue breast-feeding на Английски и техните преводи на Български
{-}
-
Medicine
-
Colloquial
-
Official
-
Ecclesiastic
-
Ecclesiastic
-
Computer
Discontinue breast-feeding before starting to take Rebetol.
Patients taking Rapamune should discontinue breast-feeding.
You must discontinue breast-feeding during Gemzar treatment.
Because doxorubicin hydrochloride may be harmful to nursing infants,women must discontinue breast-feeding before starting treatment with Caelyx.
Discontinue breast-feeding before starting to take this medicine.
If you are breast-feeding; you must discontinue breast-feeding during treatment with Armisarte.
Discontinue breast-feeding before starting to take Ribavirin BioPartners.
If you are breast-feeding; you must discontinue breast-feeding during treatment with Pemetrexed Fresenius Kabi.
Since this product will pass into your milk andmay adversely affect the breast-fed child, you should discontinue breast-feeding while taking Suboxone.
Women should discontinue breast-feeding during treatment with Polivy.
Because human IgG is excreted in human milk and because the potential for absorption and immunosuppression in the infant is unknown,women must discontinue breast-feeding.
You must discontinue breast-feeding during treatment with Pemetrexed Pfizer.
Because of the potential for serious adverse reactionsin infants exposed to{(Invented) Name}, mothers should discontinue breast-feeding during{(Invented) Name} therapy(see section 4.3).
Therefore, women must discontinue breast-feeding, as the potential for absorption and immunosuppression in the infant is unknown.
Since many medicinal products are excreted in human milk and because of the potential for adverse reactions in breast-feeding infants,mothers should discontinue breast-feeding when taking Xagrid.
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy should be made taking into account the benefit of breast-feeding to the child and the benefit of Pelzont to the woman.
It is recommended that HIV-infected mothers do not breast-feed their infantsto avoid risking postnatal transmission of HIV and that mothers should discontinue breast-feeding if they are receiving nevirapine.
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with Remeron should be made taking into account the benefit of breastfeeding to the child and the benefit of Remeron therapy to the woman.
It is recommended that HIV-infected mothers do not breast-feed their infants to avoid risking postnatal transmission of HIV andthat mothers should discontinue breast-feeding if they are receiving nevirapine.
A decision must be made on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with NeuroBloc taking into account the benefit of breast-feeding to the child and the benefit of NeuroBloc therapy to the woman.
Consistent with the recommendation that HIV-infected mothers should not breast-feed their infants under any circumstances to avoid risking postnatal transmission of HIV,mothers should discontinue breast-feeding if they are receiving APTIVUS.
Due to the unknown potential for adverse reactions in breast-feeding infants from Zontivity, discontinue breast-feeding or discontinue Zontivity; taking into account the importance of the medicinal product to the mother.
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with Vedrop should be made taking into account the benefit of breast-feeding to the child and the benefit of tocofersolan therapy to the woman.
Therefore, a decision to continue/discontinue breast-feeding or to continue/discontinue therapy with Efexor should be made, taking into account the benefit of breast-feeding to the child and the benefit of Efexor therapy to the woman.
A decision on whether to continue/ discontinue breast-feeding or to continue/ discontinue therapy with Remeron should be made taking into account the benefit of breast- feeding to the child and the benefit of Remeron therapy to the woman.
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with Rilonacept Regeneron should be made taking into account the benefit of breast-feeding to the child and the benefit of Rilonacept Regeneron therapy to the woman.
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with RoActemra should be made taking into account the benefit of breast-feeding to the child and the benefit of RoActemra therapy to the woman.
Therefore a decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with Protium should be made taking into account the benefit of breastfeeding to the child and the benefit of Protium therapy to women.
A decision on whether to continue/discontinue breast-feeding or to continue/discontinue therapy with NovoSeven should be made taking into account the benefit of breast-feeding to the child and the benefit of NovoSeven therapy to the woman.
A decision on whether to continue/ discontinue breast-feeding or to continue/ discontinue therapy with Altargo should be made taking into account the benefit of breast-feeding to the child and the benefit of Altargo therapy to the woman.